Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020109818 - DIFFERENTIAL METHYLATION

Publication Number WO/2020/109818
Publication Date 04.06.2020
International Application No. PCT/GB2019/053386
International Filing Date 29.11.2019
IPC
G16B 99/00 2019.01
GPHYSICS
16INFORMATION AND COMMUNICATION TECHNOLOGY SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
99Subject matter not provided for in other groups of this subclass
G16B 40/00 2019.01
GPHYSICS
16INFORMATION AND COMMUNICATION TECHNOLOGY SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
40ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
C12Q 1/6886 2018.01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
6883for diseases caused by alterations of genetic material
6886for cancer
CPC
C12Q 1/6886
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms
68involving nucleic acids
6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
6883for diseases caused by alterations of genetic material
6886for cancer
C12Q 2600/154
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS
2600Oligonucleotides characterized by their use
154Methylation markers
Applicants
  • UCL BUSINESS LTD [GB]/[GB]
Inventors
  • TEIXEIRA, Vitor Hugo De Sousa
  • JANES, Samuel
  • PIPINIKAS, Christodoulos P.
  • PENNYCUICK, Adam James
Agents
  • J A KEMP LLP
Priority Data
1819452.229.11.2018GB
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) DIFFERENTIAL METHYLATION
(FR) MÉTHYLATION DIFFÉRENTIELLE
Abstract
(EN)
The present invention relates to a method of identifying whether or not an individual has a cancer, a pre-invasive lesion that will progress to a cancer, or a pre- cancerous cell population that will progress to a cancer based on a methylation heterogeneity index (MHI). The present invention also relates to a method of treating and/or preventing a cancer and/or treating a pre-invasive lesion that will progress to a cancer or a pre- cancerous cell population that will progress to a cancer in an individual, the method comprising: identifying a cancer, a pre-invasive lesion that will progress to a cancer, or a pre-cancerous cell population that will progress to a cancer based on an MHI. The present invention also relates to an MHI and uses thereof, for identifying in an individual a cancer, a pre-invasive lesion that will progress to a cancer, or a pre- cancerous cell population that will progress to a cancer.
(FR)
La présente invention concerne un procédé destiné à identifier si un individu a un cancer, une lésion pré-invasive qui va évoluer en cancer, ou une population de cellules précancéreuses qui va évoluer en cancer sur la base d'un indice d'hétérogénéité de méthylation (MHI). La présente invention concerne également un procédé de traitement et/ou de prévention d'un cancer et/ou de traitement d'une lésion pré-invasive qui va évoluer en cancer ou d'une population de cellules précancéreuses qui va évoluer en cancer chez un individu, le procédé comprenant : l'identification d'un cancer, d'une lésion pré-invasive qui va évoluer en cancer, ou d'une population de cellules précancéreuses qui va évoluer en cancer sur la base d'un MHI. La présente invention concerne également un MHI et ses utilisations, destinés à identifier chez un individu un cancer, une lésion pré-invasive qui va évoluer en cancer, ou une population de cellules précancéreuses qui va évoluer en cancer.
Latest bibliographic data on file with the International Bureau